How to buy OPKO Health stock | $4.44

OPKO Health, Inc is a diagnostics & research business based in the US. OPKO Health shares (OPK) are listed on the NASDAQ and all prices are listed in US Dollars. OPKO Health employs 5,269 staff and has a trailing 12-month revenue of around 0.00.

OPKO Health share price

Use our graph to track the performance of OPK stocks over time.

OPKO Health shares at a glance

• Key figures

Information last updated 2021-05-08.

Latest market close	$4.44
52-week range	$2.08 - $6.47
50-day moving average	$4.28
200-day moving average	$4.44
Wall St. target price	$8.25
PE ratio	20.1058
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.19

Buy OPKO Health shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy OPKO Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of OPKO Health, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

OPKO Health price performance over time

Historical closes compared with the close of $4.44 from 2021-03-11

1 week (2021-05-04)	12.12%
1 month (2021-04-09)	6.22%
3 months (2021-02-11)	-19.57%
6 months (2020-11-11)	20.00%

1 year (2020-05-11)	85.77%
2 years (2019-05-10)	109.43%
3 years (2018-05-11)	4.52
5 years (2016-05-11)	9.93

Is OPKO Health under- or over-valued?

Valuing OPKO Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of OPKO Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

OPKO Health's P/E ratio

OPKO Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, OPKO Health shares trade at around 20x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

OPKO Health's EBITDA

OPKO Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $216.1 million.

The EBITDA is a measure of a OPKO Health's overall financial performance and is widely used to measure a its profitability.

OPKO Health financials

Revenue TTM	$1.8 billion
Operating margin TTM	7.51%
Gross profit TTM	$541 million
Return on assets TTM	3.49%
Return on equity TTM	7.45%
Profit margin	6.83%
Book value	$2.53
Market capitalisation	$2.5 billion

TTM: trailing 12 months

Shorting OPKO Health shares

There are currently 78.7 million OPKO Health shares held short by investors – that's known as OPKO Health's "short interest". This figure is 3.5% down from 81.6 million last month.

There are a few different ways that this level of interest in shorting OPKO Health shares can be evaluated.

OPKO Health's "short interest ratio" (SIR)

OPKO Health's "short interest ratio" (SIR) is the quantity of OPKO Health shares currently shorted divided by the average quantity of OPKO Health shares traded daily (recently around 5.1 million). OPKO Health's SIR currently stands at 15.33. In other words for every 100,000 OPKO Health shares traded daily on the market, roughly 15330 shares are currently held short.

However OPKO Health's short interest can also be evaluated against the total number of OPKO Health shares, or, against the total number of tradable OPKO Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OPKO Health's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 OPKO Health shares in existence, roughly 120 shares are currently held short) or 0.1965% of the tradable shares (for every 100,000 tradable OPKO Health shares, roughly 197 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against OPKO Health.

Find out more about how you can short OPKO Health stock.

OPKO Health share dividends

We're not expecting OPKO Health to pay a dividend over the next 12 months.

OPKO Health share price volatility

Over the last 12 months, OPKO Health's shares have ranged in value from as little as $2.08 up to $6.47. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OPKO Health's is 1.7743. This would suggest that OPKO Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

OPKO Health overview

OPKO Health, Inc. , a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico.

Frequently asked questions

• What percentage of OPKO Health is owned by insiders or institutions?

  Currently 40.255% of OPKO Health shares are held by insiders and 29.101% by institutions.

• How many people work for OPKO Health?

  Latest data suggests 5,269 work at OPKO Health.

• When does the fiscal year end for OPKO Health?

  OPKO Health's fiscal year ends in December.

• Where is OPKO Health based?

  OPKO Health's address is: 4400 Biscayne Boulevard, Miami, FL, United States, 33137

• What is OPKO Health's ISIN number?

  OPKO Health's international securities identification number is: US68375N1037

• What is OPKO Health's CUSIP number?

  OPKO Health's Committee on Uniform Securities Identification Procedures number is: 23282G105